Drotrecogin alfa
Pharmaceutical drug / From Wikipedia, the free encyclopedia
Dear Wikiwand AI, let's keep it short by simply answering these key questions:
Can you list the top facts and stats about Drotrecogin alfa?
Summarize this article for a 10 year old
SHOW ALL QUESTIONS
Drotrecogin alfa (activated) (Xigris, marketed by Eli Lilly and Company) is a recombinant form of human activated protein C that has anti-thrombotic, anti-inflammatory, and profibrinolytic properties. Drotrecogin alpha (activated) belongs to the class of serine proteases. Drotrecogin alfa has not been found to improve outcomes in people with severe sepsis. The manufacturer's aggressive strategies in marketing its use in severe sepsis have been criticized.[1] On October 25, 2011, Eli Lilly & Co. withdrew Xigris from the market after a major study showed no efficacy for the treatment of sepsis.[2][3]
Quick Facts Clinical data, Trade names ...
Clinical data | |
---|---|
Trade names | Xigris |
AHFS/Drugs.com | Monograph |
Routes of administration | Intravenous |
ATC code | |
Legal status | |
Legal status |
|
Pharmacokinetic data | |
Bioavailability | 100% (i.v. application only) |
Metabolism | endogenous plasma protease inhibitors |
Elimination half-life | less than 2 hours |
Identifiers | |
| |
CAS Number | |
IUPHAR/BPS | |
DrugBank |
|
ChemSpider |
|
UNII | |
Chemical and physical data | |
Formula | C1786H2779N509O519S29 |
Molar mass | 40615.66 g·mol−1 |
NY (what is this?) (verify) |
Close